http://www.biospace.comBioSpace RSS GeneratorSat, 07 Nov 2009 04:51:33 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2009http://www.biospace.com/news_story.aspx?StoryID=162017&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162004&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162063&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162002&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162006&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162015&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161999&full=1PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ to include long-term data from the CASTLE Study. The CASTLE Study assessed a once-daily REYATAZ/ritonavir (REYATAZ/r)-based regimen versus a twice-daily lopinavir/ritonavir (LPV/r)-based regimen in previously untreated...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162019&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162026&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161993&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161991&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162001&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161997&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162058&full=1NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. As previously announced, having achieved the study-specified efficacy milestone...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162085&full=1<p> PARIS, November 6 /PRNewswire/ --</p><p> - Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections</p><p> Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162104&full=1<p>CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162027&full=1<p></p><p></p><p>HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS(R) continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA:</p><p></p><p></p><p>Continuous Subcutaneous Delivery of Exenatide Via ITCA 650 Lowers Plasma Glucose, HbA...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162029&full=1REDWOOD CITY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Miami Beach, Florida from November 5 to 7, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162031&full=1BERKELEY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta (IL-1 beta) to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162054&full=1CAMBRIGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the companys clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM). Genetix is planning...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162093&full=1LONDON--(BUSINESS WIRE)--The first public data on Ossulin a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited (www.cmdpharmaltd.com) and Natreon Inc., New Brunswick, NJ., developers of the proprietary...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162088&full=1<p></p><p>RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a broad-spectrum antiviral...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162089&full=1<p></p><p>SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration with scientists at the Centers for Disease Control and Prevention (CDC), St. Louis University, and the University of Hong Kong, announced today the publication of two articles in the peer-reviewed journal PLoS ONE. These two published studies suggest that DAS181 (Fludase(R)) may play a potentially important role for the treatment...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162103&full=1<p> VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.</p><p> The agreement gives EUCODIS Bioscience exclusive access - for the search of enzymes of interest...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162045&full=1WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today announced it has completed its acquisition of Excel PharmaStudies, Inc., the market leader and one of the largest contract research organizations in China. The acquisition strengthens PPDs full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162053&full=1EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Life Sciences Research, Inc. (NYSE Arca: LSR) announced today that RiskMetrics Group (formerly Institutional Shareholder Services), a leading proxy advisory firm, has recommended that LSR stockholders vote FOR the approval of the merger of LSR and Lion Merger Corp. pursuant to the Agreement and Plan of Merger, dated as of July 8, 2009, among LSR, Lion Merger...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162108&full=1<p></p><p></p><p>SPRING VALLEY, Calif., Nov. 6 /PRNewswire/ -- Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus. </p><p></p><p></p><p>Technology developed...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162125&full=1<div id"releaseBody"><div class"releaseMediaMW"><img src"http://media.marketwire.com/attachments/200911/TN-583818_VIBATIV.jpg" alt""><br><a href"http://www2.marketwire.com/mw/frame_multimedia?prid555982&attachid1107919">(Click here for details)<br> </a></div><p>SOUTH SAN FRANCISCO, CA and DEERFIELD, IL--(Marketwire - November 05, 2009) - Theravance, Inc.(NASDAQ: <a href"http://www.marketwire...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162091&full=1<p></p><p>NOVATO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that the United States Patent and Trademark Office has issued a patent covering the approved administration of Kuvan(R) (sapropterin dihydrochloride) with food for the treatment of phenylketonuria (PKU). The patent expires in 2024.</p><p></p><p></p><p>About Kuvan</p><p></p><p></p><p>Kuvan has received...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161992&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162040&full=1NEW YORK, Nov. 5, 2009 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Hana Biosciences, Inc. Hana Biosciences, Inc.'s stock was suspended on September 10, 2009 and has not traded on NASDAQ since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162043&full=1BLUE BELL, Pa.--(BUSINESS WIRE)--Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel. Ansaris...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162106&full=1<p></p><p></p><p>SAN DIEGO, Nov. 5 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development. This investment in an experienced...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162032&full=1NEW HAVEN, Conn., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and nine months ended September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $6.4 million, compared with a...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162033&full=1LAKE SUCCESS, N.Y., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of chemically derived pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal 2010 first quarter ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162041&full=1CLEVELAND, Nov. 5, 2009 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the quarter ended September 30, 2009. Third Quarter Highlights Include: Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162072&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its second quarter of fiscal 2010, which ended on September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162075&full=1BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today reported its consolidated financial results for the quarter and nine months ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162077&full=1ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today its financial results for the third quarter and nine months ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162112&full=1<p>SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009.</p><p></p><p>(Logo: http://www.newscom.com/cgi...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162133&full=1ANN ARBOR, Mich., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today reported financial results and operational updates for the first fiscal quarter ended September 30, 2009. Aastrom continues to operate in a capital-efficient manner while advancing its cardiovascular clinical...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162065&full=1<p>LYNBROOK, N.Y., Nov. 5 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. , a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.</p><p></p><p>"We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommended, by a vote of...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162070&full=1FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and nine months ended September 30, 2009. For the three months ended September 30, 2009, the Company reported a net loss of $7.9 million, or $0.36 per diluted share, compared to a net loss of $18.0 million, or $0.97 per diluted share, for the same period in 2...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162100&full=1<p></p><p></p><p>BELLEVILLE, ON, Nov. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.</p><p>"We ended the first quarter of Fiscal 2010 in a strong position, with current assets of $25.3 million, 53% of which is cash," stated...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162130&full=1<div id"releaseBody"><p>IRVINE, CA--(Marketwire - November 05, 2009) - BIOLASE Technology, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBLTI">BLTI</a>), theworld's leading dental laser company, today reported operating results forthe 2009 third quarter and nine months ended September 30, 2009.<p>Net revenue for the third quarter of 2009 was $12.1 million, compared...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162096&full=1<p></p><p>SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2009.</p><p></p><p></p><p>Financial Results</p><p>For the three months ended...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162102&full=1<p>EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Bionovo, Inc. , a drug discovery and development company focused on the unmet needs in women's health and oncology, today announced third quarter highlights and financial results for the three months ended September 30, 2009.</p><p></p><p>Subsequent to the end of the quarter, in October 2009, Bionovo successfully completed a public offering and...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162135&full=1COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ:CLSN), a late stage clinical oncology development company that is leveraging its heat activated liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it will hold a conference call to discuss third quarter 2009 results at 11:00 a.m. Eastern Time on Tuesday, November ...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162083&full=1<p>WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R) , a dermatology company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the third quarter ended September 30, 2009.</p><p></p><p>Third quarter and year-to-date...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162034&full=1HAMBURG, Germany, Nov. 6, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (Nasdaq:EVTC) will report its financial results for the third quarter of 2009 on Thursday, 12 November 2009.Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162047&full=1FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc.s ("GTC", NASDAQ: GTCB) total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162111&full=1<p>GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. today announced its financial results for the third quarter ended September 30, 2009. GenVec reported a net loss of $3.6 million ($0.04 per share) for the three months ended September 30, 2009 compared to a net loss of $6.8 million ($0.08 per share) in the comparable quarter of 2008. For the nine months ended September 30, 2009, GenVec...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162121&full=1<p>ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update.</p><p></p><p>Robert McNally, Ph.D., President and Chief...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162048&full=1SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162030&full=1MORRIS PLAINS, N.J., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the first quarter ended September 30, 2009. The Company also highlighted recent key developments and planned activities for its clinical pipeline. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162046&full=1BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162050&full=1ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162094&full=1<p>BRISBANE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced results from operations for the third quarter and nine months ended September 30, 2009. InterMune reported a net loss for the third quarter of 2009 of $8.8 million, or $0.19 per share, compared with a net loss of $14.0 million, or $0.36 per share, in the third quarter of 2008.</p><p></p><p>Dan Welch, Chairman, Chief...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162113&full=1<p></p><p>RICHMOND, Va., Nov. 6 /PRNewswire-FirstCall/ -- Insmed Inc. , a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2009.</p><p></p><p></p><p>The net loss for the third quarter of 2009 was $150,000; break even on a dollar per share basis, compared with a net loss of $2.2 million, or $0.02 per share, in the third quarter of 2008. This...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162066&full=1<p></p><p></p><p>PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2009. </p><p></p><p></p><p>"Our sales team delivered another solid quarter for us with record numbers of XYREM and LUVOX CR prescriptions and net sales" said Bob Myers, President of Jazz Pharmaceuticals. </p><p></p><p></p><p>Jazz...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162074&full=1SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (the Company or Ligand) today announced financial results for the three and nine months ended September 30, 2009 and provided a business update. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162081&full=1<p></p><p></p><p>LAVAL, QC, Nov. 6 /PRNewswire-FirstCall/ - Labopharm Inc. today reported its financial results for the third quarter ended September 30, 2009. All figures are in Canadian dollars unless otherwise stated.</p><p>"We have made strong progress in recent months towards the commercialization of our novel trazodone formulation in both the United States and Canada," said James R. Howard...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162082&full=1EAST MILLSTONE, N.J.--(BUSINESS WIRE)--Life Sciences Research, Inc. (NYSE Arca: LSR) announced today financial results for the three and nine months ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162079&full=1REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced financial results for the quarter ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162038&full=1ROCKVILLE, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the quarter ended September 26, 2009. The Company reported a net loss from continuing operations of $7.0 million, or $0.14 per share, compared to a net loss of $4.6 million, or $0.09 per share, for the period ended September 27, 2008. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162090&full=1BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (NASDAQ: NRGN), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009. The Company also announced its analysis of results from a previously suspended Phase 2 study of aplindore in Restless Legs Syndrome (RLS) and...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162116&full=1<p>ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. today announced financial results for the third quarter ended September 30, 2009 and reviewed its recent accomplishments and upcoming milestones.</p><p></p><p>Novavax's net loss for the third quarter of 2009 was $7.5 million, or $0.08 per share, compared to a net loss of $7.8 million, or $0.12 per share, for the same period last year...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162120&full=1<p>SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ --</p><p></p><p>3Q09 Corporate Highlights:</p><p></p><p>Upcoming 2009 Milestones:</p><p></p><p></p><p>NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the third quarter ended September 30, 2009.</p><p></p><p>During the third quarter of 2009, NeurogesX...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162131&full=1<div id"releaseBody"><p>TORONTO, ONTARIO--(Marketwire - November 05, 2009) - Novadaq&#174; Technologies Inc. (TSX: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSX:NDQ">NDQ</a>), a developer of real-time medical imaging systems for the operating room, announced today that it is expanding the scope of its Q3-2009 financial results conference call, scheduled for November 12, 2009 at 1...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162067&full=1<p>EATONTOWN, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Osteotech, Inc. , a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the third quarter ended September 30, 2009.</p><p></p><p>"During the third quarter of 2009, our focus was on the release of our three new biologic products MagniFuse(TM) Bone Graft, FacetLinx(TM) Fusion Technology...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162068&full=1<p>Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time</p><p></p><p>BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009.</p><p>The following...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162114&full=1<p>WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today reported results for the third quarter ended October 3, 2009.</p><p></p><p>For the third quarter ended October 3, 2009, Par reported total revenues of $294.8 million and net income of $26.3 million, or $0.76 per diluted share. This is compared to reported revenues of $149.0 million and net income of...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162049&full=1IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced the date and time for its third quarter 2009 corporate update and pipeline review conference call. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162076&full=1SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the third quarter...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162123&full=1<div id"releaseBody"><p>LONDON, ONTARIO--(Marketwire - November 06, 2009) - Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerSLXCF">SLXCF</a>), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced its financial results for the third quarter...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162042&full=1REDWOOD CITY, Calif., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162071&full=1<p></p><p>POINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will host a webcast and teleconference with management to discuss third quarter 2009 financial results...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162073&full=1<p>SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. today announced financial results for its third quarter and nine months ended Sept. 30, 2009.</p><p></p><p>(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)</p><p></p><p>Third Quarter and Nine Months 2009 Financial Results </p><p>Revenue for the third quarter and nine months ended Sept. 30, 2009, was $4.5 million...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162080&full=1WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today reported its financial results for the third quarter ended September 30, 2009. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162095&full=1<p>RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. , a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the first quarter of fiscal 2010.</p><p></p><p>For the quarter ended September 30, 2009, the Company reported revenues of $5.2 million, a 15 percent increase over revenues of $4.5 million in the first quarter...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162098&full=1SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today reported improved financial results for the third quarter ended September 30, 2009. The companys net loss for the quarter declined substantially to $11.4 million, or $0.17 per share, from $28.8 million, or $0.42 per share, for the third quarter of 2008. Revenues for the third quarter of 2009 increased by 131% compared to the third quarter...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162060&full=1DUBLIN--(BUSINESS WIRE)--Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of John F. Thero as the Companys Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate development and other strategic and operational matters. He will report directly to Dr. Declan Doogan...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162057&full=1LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced today the appointment of Julie Lekstrom Himes, M.D. to join TARIS in the position of Chief Medical Officer and Senior Vice President for Clinical Development. Dr. Himes has broad clinical research and operations experience within the...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162061&full=1TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has appointed Bernard R. Tyrrell as the Companys Senior Vice President, Sales and Marketing, a newly created position. Mr. Tyrrell joins EpiCept with a wealth of experience in pharmaceutical marketing and business development, both in the U.S. and internationally. Most...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162084&full=1CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Companys Board of Directors effective immediately. Mr. Rothwells appointment fills the vacancy created by Franklin Berger, who recently resigned from the Board in order to focus more time on certain other business endeavors...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162110&full=1REDMOND, Wash.--(BUSINESS WIRE)--Visitors to the newly branded and redesigned website of the Washington Biotechnology & Biomedical Association (WBBA) to be featured at the WBBAs Annual Meeting today will get free, timely, Washington state-focused biotech and medtech news through its Economic Issues in WA Healthcare Breaking News feature. This new feature, powered by MedIntelliBase Intelligence...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162069&full=1WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Thirty-two Purdue University faculty and staff will be recognized at the Purdue Research Foundation's annual Inventors Recognition Dinner on Thursday (Nov. 5). Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162134&full=1WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the Mass Technology Leadership Council, Inc. named Phase Forward Private Sector Company of the Year at the 2009 Mass Technology Leadership Awards in Boston last night. Honoring Massachusetts companies and individuals who best exemplify leadership...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162052&full=1BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) today announced that William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, is scheduled to speak at the Credit Suisse 18th Annual Healthcare Conference in Phoenix AZ. LabCorps presentation is planned for Friday, November 13, 2009 at 9:30 a.m. (Mountain Standard Time). Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162056&full=1BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its presentation at the 2009 Annual Credit Suisse Health Care Conference will be webcast and may be accessed at www.sucampo.com.Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162078&full=1<p></p><p>SAN DIEGO, Nov. 5, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the 18th Annual Credit Suisse Healthcare Conference in Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. PT / 1:00 p.m. ET. Mark Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals, will be providing a corporate overview.</p><p><...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162087&full=1ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced that it will present at the 18th Annual Credit Suisse Healthcare Conference to be held November 11-13, 2009 at the Arizona Biltmore Resort & Spa in Phoenix, Arizona. Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=162092&full=1BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to provide a live webcast of its presentation scheduled for Thursday, November 12, 2009, at 9:00 am Mountain Standard Time (11:00 am Eastern Standard Time), at the Credit Suisse 2009 Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona. The presentation may include a discussion of the Company...Fri, 06 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161835&full=1Philly.com -- Johnson & Johnson said today that it was closing research & development facilities in Radnor and Chesterbrook and consolidating those operations at the company's Spring House site.Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161852&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161822&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161810&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161825&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161838&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161626&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161818&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161853&full=1<p></p><p>NOVATO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. , today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.</p><p></p><p></p><p>Mark...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161836&full=1Bloomberg -- Merck & Co. Chief Executive Officer Richard T. Clark said he plans to keep Schering-Plough Corp.s headquarters after completing the acquisition of the company. Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161809&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161811&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161832&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161831&full=1Bloomberg -- Pfizer Inc. must pay about $75 million in punitive damages to an Illinois woman who developed cancer after taking one of the drugmakers menopause treatments, people familiar with a sealed verdict in the case said. Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161833&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161956&full=1<p></p><p>SOUTH SAN FRANCISCO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161616&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161451&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161814&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161840&full=1PALO ALTO, Calif., & DEERFIELD, Ill.--(Business Wire)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research &Development Center, Inc., today announced data from a Phase 2 clinical trial ofHematide showing that Hematide increased hemoglobin and reduced or eliminatedthe need for blood transfusion in most patients with erythropoietin-induced purered cell aplasia (PRCA). The...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161634&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161816&full=1 <!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161654&full=1<p></p><p>SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161889&full=1LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. The endpoint combines safety and efficacy...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161896&full=1LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161931&full=1PALO ALTO, Calif., & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA). The data...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161877&full=1MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today the presentation of data at the GHSI Public Health Emergency Medical Countermeasures Workshop detailing the potential of AEOL 10150 as a broad spectrum medical countermeasure (MCM) to treat radiological and chemical threats. Data presented from studies sponsored by Aeolus, the National Institutes of Health...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161888&full=1PITTSBURGH--(BUSINESS WIRE)--Cellumen, Inc., a discovery and early safety assessment company, today announced that its in vitro Rat Hepatocyte Early Safety Assessment Panel provides increased predictivity for human drug induced liver injury (DILI) equivalent to that of a recently published panel comprised of human hepatocytes. The implications of this study have a significant impact on cost and throughput...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161924&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi. In...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161979&full=1MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Complete Genomics, a third-generation human genome sequencing company, today announced publication of a report in the journal Science describing its proprietary DNA sequencing platform, including analysis of sequence data from three complete human genomes. The consumables cost for these three genomes sequenced on the proof-of-principle genomic DNA nanoarrays...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161862&full=1BETHESDA, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune's rights to blinatumomab in North America, and to terminate the collaboration agreement signed in...Thu, 05 Nov 2009 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=161850&full=1NORTHVALE, N.J., Nov. 5, 2009 (GLOBE NEWSWIRE) -- On October 30, 2009, Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) completed the second closing of the Strategic Alliance Agreement (the "Alliance") with Epic Pharma, LLC and Epic Investments, LLC, a wholly-owned subsidiary of Epic Pharma, LLC (collectively "Epic") pursuant to the terms in the Alliance entered into on March 18, 2009 and previously...Thu, 05 Nov 2009 12:00:00 AM GMT